Last reviewed · How we verify
Utidelone combined with Bevacizumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab) — Beijing Biostar Pharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Utidelone combined with Bevacizumab TARGET | Utidelone combined with Bevacizumab | Beijing Biostar Pharmaceuticals Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Utidelone combined with Bevacizumab CI watch — RSS
- Utidelone combined with Bevacizumab CI watch — Atom
- Utidelone combined with Bevacizumab CI watch — JSON
- Utidelone combined with Bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). Utidelone combined with Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/utidelone-combined-with-bevacizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab